Treatment Options for Statin-Associated Muscle Symptoms
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
BACKGROUND: About 4.6 million persons in Germany are now taking statins, i.e., drugs that inhibit the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMGCoA) reductase. Statins lower the concentration of low-density lipoproteins (LDL) and thereby lessen the rate of cardiovascular events; the size of this effect depends on the extent of lowering of the LDL cholesterol concentration. Muscle symptoms are a clinically relevant side effect of statin treatment. METHODS: This review is based on pertinent publications retrieved by a selective literature search, and on the current recommendations of the European Atherosclerosis Society. RESULTS: At least 5% of patients taking statins have statin-associated muscle symptoms (SAMS). The etiology of SAMS is heterogeneous. SAMS may seriously impair quality of life and cause complications of variable severity, up to and including rhabdomyolysis (in about 1 in 100,000 cases). SAMS often lead to a reduction in the prescribed dose of the statin, while also negatively affecting drug adherence. More than 90% of patients with SAMS can keep on taking statins over the long term and gain the full clinical benefit of statin treatment after a switch to another type of statin or a readjustment of the dose or frequency of administration. If the LDL cholesterol concentration is not adequately lowered while the patient is taking a statin in the highest tolerable dose, combination therapy is indicated. CONCLUSION: SAMS are important adverse effects of statin treatment because they lessen drug adherence. Patients with SAMS should undergo a thorough diagnostic evaluation followed by appropriate counseling. In most cases, statins can be continued, with appropriate adjustments, even in the aftermath of SAMS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Collaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443
Self-citationBruckert, E., Hayem, G., Dejager, S., Yau, C., & Bégaud, B. (2005) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-005-5686-z · Cited by 1,226
Adherence with statin therapy in elderly patients with and without acute coronary syndromes
Jackevicius, C. A. (2002) · JAMA · doi:10.1001/jama.288.4.462 · Cited by 1,077
Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences
Chowdhury, R., Khan, H., Heydon, E., Shroufi, A., Fahimi, S., Moore, C., Stricker, B., Mendis, S., Hofman, A., Mant, J., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht295 · Cited by 931
The safety of statins in clinical practice
Armitage, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60716-8 · Cited by 833
Statin Safety: A Systematic Review
Law, M., & Rudnicka, A. R. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.010 · Cited by 808 · cited 2×
“Of particular clinical relevance, the effective concentration of statins can be increased by the concomitant use of medications that interfere with statin degradation, such as macrolide antibiotics or azole antifungals, or grape-fruit juice (eBox 1) (11, 19).”
Safety of anacetrapib in patients with or at high risk for coronary heart disease
Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., Stepanavage, M., Liu, S. X., Gibbons, P., Ashraf, T. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1009744 · Cited by 749
Wanner, C., the Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members, & Tonelli, M. (2014) · Kidney International · doi:10.1038/ki.2014.31 · Cited by 649
Statin-associated myopathy with normal creatine kinase levels
Phillips, P. S., Haas, R. H., Bannykh, S., Hathaway, S., Gray, N. L., Kimura, B. J., Vladutiu, G. D., England, J. D. F., & and the Scripps Mercy Clinical Research Center* (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-7-200210010-00009 · Cited by 565
Discontinuation of Statins in Routine Care Settings: A Cohort Study
Zhang, H., Plutzky, J., Skentzos, S., Morrison, F., Mar, P., Shubina, M., & Turchin, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-7-201304020-00004 · Cited by 548
Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance
Stroes, E., Colquhoun, D., Sullivan, D., Civeira, F., Rosenson, R. S., Watts, G. F., Bruckert, E., Cho, L., Dent, R., Knusel, B., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.019 · Cited by 526
Pfeifer, M., Begerow, B., & Minne, H. W. (2002) · Osteoporosis International · doi:10.1007/s001980200012 · Cited by 521
Effect of statins on skeletal muscle function
Parker, B. A., Capizzi, J. A., Grimaldi, A. S., Clarkson, P. M., Cole, S. M., Keadle, J., Chipkin, S., Pescatello, L. S., Simpson, K., White, C. M., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.136101 · Cited by 500
Cohen, J. D., Brinton, E. A., Ito, M. K., & Jacobson, T. A. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.03.003 · Cited by 486
An assessment by the statin muscle safety task force: 2014 update
Rosenson, R. S., Baker, S. K., Jacobson, T. A., Kopecky, S. L., & Parker, B. A. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.03.004 · Cited by 485
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
Pasanen, M. K., Neuvonen, M., Neuvonen, P. J., & Niemi, M. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230416.82349.90 · Cited by 470
Narrative review: statin-related myopathy
Joy, T. R., & Hegele, R. A. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-12-200906160-00009 · Cited by 453
Nicholls, S. J., Brewer, H. B., Kastelein, J. J. P., Krueger, K. A., Wang, M.-D., Shao, M., Hu, B., McErlean, E., & Nissen, S. E. (2011) · JAMA · doi:10.1001/jama.2011.1649 · Cited by 410
Naci, H., Brugts, J., & Ades, T. (2013) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.111.000071 · Cited by 292
Effect of Coenzyme Q10 on myopathic symptoms in patients treated with statins
Caso, G., Kelly, P., McNurlan, M. A., & Lawson, W. E. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.12.063 · Cited by 286
A systematic review of statin-induced muscle problems in clinical trials
Ganga, H. V., Slim, H. B., & Thompson, P. D. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.03.019 · Cited by 253 · cited 1×
“The incidence of muscle symptoms in randomized trials was low, with little difference between the statin and placebo groups (7–9, e15, e16), which could be attributed to numerous factors.”
Genetic risk factors associated with lipid-lowering drug-induced myopathies
Vladutiu, G. D., Simmons, Z., Isackson, P. J., Tarnopolsky, M., Peltier, W. L., Barboi, A. C., Sripathi, N., Wortmann, R. L., & Phillips, P. S. (2006) · Muscle & Nerve · doi:10.1002/mus.20567 · Cited by 253
Tonelli, M., Wanner, C., & for the Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members* (2014) · Annals of Internal Medicine · doi:10.7326/m13-2453 · Cited by 226
A statin-dependent QTL for GATM expression is associated with statin-induced myopathy
Mangravite, L. M., Engelhardt, B. E., Medina, M. W., Smith, J. D., Brown, C. D., Chasman, D. I., Mecham, B. H., Howie, B., Shim, H., Naidoo, D., et al. (2013) · Nature · doi:10.1038/nature12508 · Cited by 224
Human skeletal muscle drug transporters determine local exposure and toxicity of statins
Knauer, M. J., Urquhart, B. L., Meyer zu Schwabedissen, H. E., Schwarz, U. I., Lemke, C. J., Leake, B. F., Kim, R. B., & Tirona, R. G. (2010) · Circulation Research · doi:10.1161/circresaha.109.203596 · Cited by 222
DeGorter, M. K., Tirona, R. G., Schwarz, U. I., Choi, Y.-H., Dresser, G. K., Suskin, N., Myers, K., Zou, G., Iwuchukwu, O., Wei, W.-Q., et al. (2013) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.113.000099 · Cited by 195
Muscle coenzyme Q10 level in statin-related myopathy
Lamperti, C., Naini, A. B., Lucchini, V., Prelle, A., Bresolin, N., Moggio, M., Sciacco, M., Kaufmann, P., & DiMauro, S. (2005) · Archives of Neurology · doi:10.1001/archneur.62.11.1709 · Cited by 178
Mancini, G. B. J., Tashakkor, A. Y., Baker, S., Bergeron, J., Fitchett, D., Frohlich, J., Genest, J., Gupta, M., Hegele, R. A., Ng, D. S., et al. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.09.023 · Cited by 173
Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience
Mampuya, W. M., Frid, D., Rocco, M., Huang, J., Brennan, D. M., Hazen, S. L., & Cho, L. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.06.004 · Cited by 173
Lipin-1 regulates autophagy clearance and intersects with statin drug effects in skeletal muscle
Zhang, P., Verity, M. A., & Reue, K. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.05.003 · Cited by 166
Association between statin-associated myopathy and skeletal muscle damage
Mohaupt, M. G., Karas, R. H., Babiychuk, E. B., Sanchez-Freire, V., Monastyrskaya, K., Iyer, L., Hoppeler, H., Breil, F., & Draeger, A. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.081785 · Cited by 166
Moriarty, P. M., Jacobson, T. A., Bruckert, E., Thompson, P. D., Guyton, J. R., Baccara-Dinet, M. T., & Gipe, D. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.09.007 · Cited by 154
Chodick, G., Shalev, V., Gerber, Y., Heymann, A. D., Silber, H., Simah, V., & Kokia, E. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.11.012 · Cited by 145
Impact of genetic variation in OATP transporters to drug disposition and response
Gong, I. Y., & Kim, R. B. (2013) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-12-rv-099 · Cited by 137
Statin use and musculoskeletal pain among adults with and without arthritis
Buettner, C., Rippberger, M. J., Smith, J. K., Leveille, S. G., Davis, R. B., & Mittleman, M. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.08.007 · Cited by 102
Effect of Coenzyme Q10 supplementation on statin-induced myalgias
Bookstaver, D. A., Burkhalter, N. A., & Hatzigeorgiou, C. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.04.026 · Cited by 89
Statin-associated rhabdomyolysis triggered by grapefruit consumption
Dreier, J. P., & Endres, M. (2004) · Neurology · doi:10.1212/wnl.62.4.670 · Cited by 81 · cited 1×
“Such cases include: ● Long-term treatment with drugs that increase the risk of myopathy (Box 2, eBox 1) (25) ● An increased risk of SAMS during statin therapy (e.g., due to hypothyroidism, myopathies, SAMS in family members, high muscle stress) (Box 2) ● Documentation of statin intolerance during…”
Self-citationCoenzyme Q10and selenium in statin-associated myopathy treatment
Fedacko, J., Pella, D., Fedackova, P., Hänninen, O., Tuomainen, P., Jarcuska, P., Lopuchovsky, T., Jedlickova, L., Merkovska, L., & Littarru, G. P. (2013) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2012-0118 · Cited by 76
Efflux and uptake transporters as determinants of statin response
Rodrigues, A. C. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425251003713519 · Cited by 64
Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies
Vladutiu, G. D., Isackson, P. J., Kaufman, K., Harley, J. B., Cobb, B., Christopher-Stine, L., & Wortmann, R. L. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.07.001 · Cited by 63
Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib
Davidson, M., Liu, S. X., Barter, P., Brinton, E. A., Cannon, C. P., Gotto, A. M., Leary, E. T., Shah, S., Stepanavage, M., Mitchel, Y., et al. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m032615 · Cited by 56
GATM gene variants and statin myopathy risk
Carr, D. F., Alfirevic, A., Johnson, R., Chinoy, H., van Staa, T., & Pirmohamed, M. (2014) · Nature · doi:10.1038/nature13628 · Cited by 35
The guinea pig as a preclinical model for demonstrating the efficacy and safety of statins
Madsen, C. S., Janovitz, E., Zhang, R., Nguyen-Tran, V., Ryan, C. S., Yin, X., Monshizadegan, H., Chang, M., D’Arienzo, C., Scheer, S., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.131615 · Cited by 33
Sidaway, J., Wang, Y., Marsden, A. M., Orton, T. C., Westwood, F. R., Azuma, C. T., & Scott, R. C. (2009) · Xenobiotica · doi:10.1080/00498250802585539 · Cited by 28
Obayashi, H., Nezu, Y., Yokota, H., Kiyosawa, N., Mori, K., Maeda, N., Tani, Y., Manabe, S., & Sanbuissho, A. (2011) · The Journal of Toxicological Sciences · doi:10.2131/jts.36.445 · Cited by 26
Naba, H., Kakinuma, C., Ohnishi, S., & Ogihara, T. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.11.179 · Cited by 10
Cited by
Tung, M.-C., Lan, Y.-W., Li, H.-H., Chen, H.-L., Chen, S.-Y., Chen, Y.-H., Lin, C.-C., Tu, M.-Y., & Chen, C.-M. (2020) · Scientific Reports · doi:10.1038/s41598-020-65782-8 · Cited by 57
Statin‐associated muscle symptoms—A review: Individualizing the approach to optimize care
Wiggins, B. S., Backes, J. M., & Hilleman, D. (2022) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2681 · Cited by 17
Non adherence to lipid-lowering therapy and strategies to improve adherence
Mehta, A. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2024.01.006 · Cited by 6
Metadata
- Authors
- Laufs, U., Scharnagl, H., Halle, M., Windler, E., Endres, M., & März, W.
- Venue
- Deutsches Ärzteblatt international
- Publisher
- Deutscher Arzte-Verlag GmbH
- Published
- 2015-10-30
- Volume
- 112
- Issue
- 44
- Pages
- 748-55
- ISSN
- 1866-0452 (ISSN-L)
- OpenAlex
- W2400903479
- Cited by
- 84
- References
- 54
- FWCI
- 9.70
- Type
- journal article
- Language
- de
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.